PressJuly 5, 2021 COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research.
PressJuly 2, 2021 Osmind Closes $15 Million Series A Round to Help Clinicians and Researchers Bring Innovative Mental Health Treatments to More Patients
PressJune 23, 2021 Psychedelics Biotech Company, Awakn Life Sciences, Goes Public on the NEO Exchange
PressJune 22, 2021 Red Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast Facility
PressJune 17, 2021 Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta
PressJune 17, 2021 MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
PressJune 15, 2021 CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
PressJune 15, 2021 Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
PressJune 14, 2021 Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
PressJune 11, 2021 Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom Farm – Specializing in Grow-At-Home Mushroom Kits
PressJune 9, 2021 Goodness Growth Holdings Subsidiary Resurgent Biosciences Announces Planned Expansion into Psychedelics Research and IP Development
PressJune 9, 2021 American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre
PressJune 8, 2021 Leading Psychedelic Wellness Company Delic Signs Definitive Agreement to Acquire Ketamine Infusion Centers Llc.
PressJune 7, 2021 Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine
PressJune 7, 2021 Pharmadrug’s Supersmart Launches Psilocybin Online Retail Platform in the Netherlands
PressJune 4, 2021 COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
PressJune 3, 2021 MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
